These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 17652190)

  • 1. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT.
    Testa C; Schiavina R; Lodi R; Salizzoni E; Corti B; Farsad M; Kurhanewicz J; Manferrari F; Brunocilla E; Tonon C; Monetti N; Castellucci P; Fanti S; Coe M; Grigioni WF; Martorana G; Canini R; Barbiroli B
    Radiology; 2007 Sep; 244(3):797-806. PubMed ID: 17652190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP).
    Panebianco V; Sciarra A; Lisi D; Galati F; Buonocore V; Catalano C; Gentile V; Laghi A; Passariello R
    Eur J Radiol; 2012 Apr; 81(4):700-8. PubMed ID: 21330082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis.
    Farsad M; Schiavina R; Castellucci P; Nanni C; Corti B; Martorana G; Canini R; Grigioni W; Boschi S; Marengo M; Pettinato C; Salizzoni E; Monetti N; Franchi R; Fanti S
    J Nucl Med; 2005 Oct; 46(10):1642-9. PubMed ID: 16204714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy.
    Martorana G; Schiavina R; Corti B; Farsad M; Salizzoni E; Brunocilla E; Bertaccini A; Manferrari F; Castellucci P; Fanti S; Canini R; Grigioni WF; D'Errico Grigioni A
    J Urol; 2006 Sep; 176(3):954-60; discussion 960. PubMed ID: 16890665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules?
    Van den Bergh L; Koole M; Isebaert S; Joniau S; Deroose CM; Oyen R; Lerut E; Budiharto T; Mottaghy F; Bormans G; Van Poppel H; Haustermans K
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1486-92. PubMed ID: 22284686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging--clinicopathologic study.
    Scheidler J; Hricak H; Vigneron DB; Yu KK; Sokolov DL; Huang LR; Zaloudek CJ; Nelson SJ; Carroll PR; Kurhanewicz J
    Radiology; 1999 Nov; 213(2):473-80. PubMed ID: 10551229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-grade prostatic intraepithelial neoplasia in patients with prostate cancer: MR and MR spectroscopic imaging features--initial experience.
    Hom JJ; Coakley FV; Simko JP; Lu Y; Qayyum A; Westphalen AC; Schmitt LD; Carroll PR; Kurhanewicz J
    Radiology; 2007 Feb; 242(2):483-9. PubMed ID: 17179396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D 1H MR spectroscopic imaging--correlation with pathologic findings.
    Mazaheri Y; Shukla-Dave A; Hricak H; Fine SW; Zhang J; Inurrigarro G; Moskowitz CS; Ishill NM; Reuter VE; Touijer K; Zakian KL; Koutcher JA
    Radiology; 2008 Feb; 246(2):480-8. PubMed ID: 18227542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases.
    Budiharto T; Joniau S; Lerut E; Van den Bergh L; Mottaghy F; Deroose CM; Oyen R; Ameye F; Bogaerts K; Haustermans K; Van Poppel H
    Eur Urol; 2011 Jul; 60(1):125-30. PubMed ID: 21292388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil.
    Kitajima K; Murphy RC; Nathan MA; Froemming AT; Hagen CE; Takahashi N; Kawashima A
    J Nucl Med; 2014 Feb; 55(2):223-32. PubMed ID: 24434294
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
    Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
    J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic MRI and CAD vs. choline MRS: where is the detection level for a lesion characterisation in prostate cancer?
    Schmuecking M; Boltze C; Geyer H; Salz H; Schilling B; Wendt TG; Kloetzer KH; Marx C
    Int J Radiat Biol; 2009 Sep; 85(9):814-24. PubMed ID: 19701842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative detection of prostate cancer: a comparison with 11C-choline PET, 18F-fluorodeoxyglucose PET and MR imaging.
    Watanabe H; Kanematsu M; Kondo H; Kako N; Yamamoto N; Yamada T; Goshima S; Hoshi H; Bae KT
    J Magn Reson Imaging; 2010 May; 31(5):1151-6. PubMed ID: 20432351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localized prostate cancer: effect of hormone deprivation therapy measured by using combined three-dimensional 1H MR spectroscopy and MR imaging: clinicopathologic case-controlled study.
    Mueller-Lisse UG; Vigneron DB; Hricak H; Swanson MG; Carroll PR; Bessette A; Scheidler J; Srivastava A; Males RG; Cha I; Kurhanewicz J
    Radiology; 2001 Nov; 221(2):380-90. PubMed ID: 11687679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral zone prostate cancer: accuracy of different interpretative approaches with MR and MR spectroscopic imaging.
    Westphalen AC; Coakley FV; Qayyum A; Swanson M; Simko JP; Lu Y; Zhao S; Carroll PR; Yeh BM; Kurhanewicz J
    Radiology; 2008 Jan; 246(1):177-84. PubMed ID: 18024434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localizing prostate cancer in the presence of postbiopsy changes on MR images: role of proton MR spectroscopic imaging.
    Kaji Y; Kurhanewicz J; Hricak H; Sokolov DL; Huang LR; Nelson SJ; Vigneron DB
    Radiology; 1998 Mar; 206(3):785-90. PubMed ID: 9494502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system.
    Jung JA; Coakley FV; Vigneron DB; Swanson MG; Qayyum A; Weinberg V; Jones KD; Carroll PR; Kurhanewicz J
    Radiology; 2004 Dec; 233(3):701-8. PubMed ID: 15564406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of prostate cancer with magnetic resonance imaging: optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coefficient mapping sequences and MR spectroscopy, correlated with biopsy and histopathological findings.
    Aydin H; Kizilgöz V; Tatar IG; Damar C; Ugan AR; Paker I; Hekimoğlu B
    J Comput Assist Tomogr; 2012; 36(1):30-45. PubMed ID: 22261768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-11 choline PET/CT imaging for differentiating malignant from benign prostate lesions.
    Li X; Liu Q; Wang M; Jin X; Liu Q; Yao S; Liu S; Li J
    Clin Nucl Med; 2008 Oct; 33(10):671-6. PubMed ID: 18806565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy.
    Reske SN; Blumstein NM; Glatting G
    Eur J Nucl Med Mol Imaging; 2008 Jan; 35(1):9-17. PubMed ID: 17828534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.